ALK bets on well-known tablet technology to treat peanut allergy
ALK has gotten the rights to use a technology by partner Catalent to develop a peanut allergy tablet vaccine. But the Danish allergy company is far from alone on the food allergy market, where biotech firms have been testing a vast array of different technologies in recent years. Still, CEO Carsten Hellmann brushes off competition.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
ALK has secured the rights to a technology it will use to develop a tablet against peanut allergy, which will be one of the most important growth drivers in the years post-2025, according to the Danish allergy company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK maintains China bet despite geopolitical unrest
For subscribers
ALK predicts 8–12 percent revenue growth in 2022
For subscribers
